---
schema_version: "secwatch.filing_event.v1"
accession: "0001650664-25-000003"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:30:38.693517+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Editas Medicine reports $270M cash, new in vivo preclinical data, and 2025-2027 strategic priorities

## Summary
- Preliminary cash, equivalents, marketable securities ~$270M as of Dec 31, 2024; operational runway into Q2 2027.
- Achieved in vivo editing of hematopoietic stem cells in non-human primates using proprietary tLNPs; further optimization underway.
- Achieved proof of concept for AsCas12a LNP delivery in liver cells in non-human primates; also demonstrated upregulation in mice.
- Anticipates declaring two in vivo development candidates by mid-2025: HSC for sickle cell/beta thalassemia and liver for undisclosed indication.
- Strategic priorities through 2027: submit at least one IND/CTA by mid-2026, start human trials H2 2026, initiate late-stage trial H2 2027.

## SEC filing metadata
- accession: 0001650664-25-000003
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000165066425000003/0001650664-25-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000165066425000003/edit-20250113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001650664-25-000003
- JSON: https://secwatch.observer/filing/0001650664-25-000003.json
- Plain text: https://secwatch.observer/filing/0001650664-25-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.